Carrington Reports Third Quarter 20... (

Carrington Reports Third Quarter 2007 Results

Date:11/27/2007

- Revenues Down from Same Quarter Last Year

- Second Consecutive Double Digit Quarter-to-Quarter Revenue Gain

- DelSite Continues Toward Phase I Vaccine Clinical Trial

IRVING, Texas, Nov. 27 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today reported revenue for the quarter ended September 30, 2007 of $6.5 million, compared to $6.7 million in the year-ago period, as the Company discontinued certain unprofitable or marginally profitable products during the third quarter of the current year. However, the revenue in the quarter just ended, was 16 percent higher than the $5.6 million revenue reported for the second quarter of 2007, the second consecutive quarter-to-quarter revenue gain this year.

Medical Services revenue for the third quarter of 2007, at $1.9 million, was down from the year-ago level of $2.3 million. Consumer Services revenue grew 5 percent for the quarter, to $3.8 million from $3.6 million in the year-ago period. Grant income received for funding of research for the Company's wholly-owned drug delivery subsidiary, DelSite Biotechnologies, Inc., decreased by 4 percent for the quarter, to $776,000 from $811,000 a year ago.

Net loss for the third quarter of 2007, including $524,000 of net funding of DelSite, was $2.2 million, or 21 cents per basic and diluted share, an increase of $485,000 from the net loss reported for the year-ago quarter of $1.7 million, or 16 cents per basic and diluted share. Pro forma loss for the quarter, exclusive of DelSite net funding, was $1.7 million compared to a $1.1 million pro forma loss in the prior-year period.

"We continue on the road to bringing growth and profitability to our core business," said Carlton E. Turner, PhD, Carrington's CEO. "Our product revenue and margins improved again this quarter as we grew our more profitable product lines and reduced our overall operating costs."

Commenting on DelSite, Dr.
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. Carrington Reports on ISO 9001:2000 Inspection
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border

Post Your Comments:

Carrington Reports Third Quarter 20...( - Revenues Down from ...)